黑色素瘤研究与常规实践中患者报告结局测量工具及其验证数据的系统综述
仅17种(15%)有黑色素瘤特异性验证数据,其中仅FACT-M问卷覆盖所有关注的心理测量变量。PROM使用高度异质,黑色素瘤特异性验证数据不足。
要点
- 黑色素瘤研究中使用的PROM种类繁多,110种工具对应124项研究。
- 仅15%的PROM有黑色素瘤特异性验证数据。
- FACT-M是唯一在所有关注心理测量变量上均有数据的工具。
核心结论
- 黑色素瘤研究与临床实践中使用的PROM高度异质,几乎每项研究对应一种独特工具。
- 仅少数工具具备黑色素瘤特异性验证数据,未来需开展心理测量评估研究填补空白。
研究设计与样本
- 系统综述与证据差距图,检索MEDLINE、Embase、Web of Science Index Medicus、CINAHL、Cochrane Central Register of Controlled Trials和PsychINFO,截至2025年1月。
主要发现
- 研究设计包括52项横断面研究(41%)、31项随机临床试验(25%)、23项纵向研究(19%)等。
- 61项研究(49%)涉及黑色素瘤治疗,其中免疫治疗最常见(24项,39%),其次为手术(7项,11%)和化疗(7项,11%)。
- 110种独特PROM中,最常评估的结局类别为患者情绪/心理幸福感(28项,25%)、健康相关生活质量(21项,19%)和患者自我功能、效能与应对策略(20项,18%)。
- 仅17种PROM(15%)有黑色素瘤特异性验证数据,其中仅FACT-M问卷在所有关注的心理测量变量上均有数据。
临床怎么用
- 临床选用PROM时应关注其是否具备黑色素瘤特异性验证数据,避免直接套用缺乏验证的工具。
- FACT-M可作为黑色素瘤患者报告结局评估的优先选项之一,因其心理测量验证较全面。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patient-reported outcome measures (PROMs) are increasingly used in melanoma research and to guide clinical practice; however, the validation of these PROMs for use in melanoma populations is unknown. OBJECTIVE: To conduct a systematic review and construct an evidence gap map to identify PROMs that have been used in melanoma research and clinical practice and related melanoma-specific validation data. EVIDENCE REVIEW: MEDLINE, Embase, Web of Science Index Medicus, CINAHL, the Cochrane Central Register of Controlled Trials, and PsychINFO were searched in January 2025 including any studies that used a PROM to evaluate outcomes of patients with melanoma published from January 1, 2010, onward to identify instruments relevant to the current era of melanoma diagnosis and treatment. FINDINGS: Of 30 895 abstracts screened, 136 articles detailing 124 studies were included in this review; a total of 32 784 participants were included. There were 52 cross-sectional studies (41%), 31 randomized clinical trials (25%), 23 longitudinal studies (19%), 8 pre-post studies (6%), 6 cohort studies (5%), 1 retrospective analysis (1%), 1 phase 4 trial (1%), 1 protocol (1%), and 1 quasi-experimental trial (1%). A total of 61 studies (49%) included a melanoma treatment, with immunotherapy being the most common (24 [39%]), followed by surgery (7 [11%]), and chemotherapy (7 [11%]). These 124 studies used 110 unique PROMs, with patient emotional/psychological well-being (28 [25%]), health-related quality of life (21 [19%]), and patient self-functioning, efficacy, and coping strategies (20 [18%]) being the most common outcome categories. Only 17 PROMs (15%) had melanoma-specific validation data available, of which only the Functional Assessment of Cancer Therapy-Melanoma questionnaire had data available for all psychometric variables of interest. CONCLUSIONS AND RELEVANCE: In this systematic review, PROMs used in melanoma research and clinical practice were heterogenous, with nearly as many unique instruments identified as studies that used them. Furthermore, few instruments had melanoma-specific validation data available. Future research should aim to address the gaps in melanoma-specific validation data of commonly used PROMs through psychometric evaluation studies to increase researchers' and clinicians' confidence in the performance and accuracy of these measures in melanoma populations.
引用
- Thompson JR, McCutcheon TB, Martin LK, et al. Patient-Reported Outcome Measures and Validation Data Used in Melanoma Research and Routine Practice: A Systematic Review. JAMA Dermatol. 2025. PMID: 40737023. doi:10.1001/jamadermatol.2025.2287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。